IL-7

Transfer of OSE Immunotherapeutics’ Shares from Compartment C to Compartment B of Euronext Paris from January 31, 2022

Retrieved on: 
Tuesday, February 1, 2022
Growth, Large-cell lung carcinoma, IND, Patient, Euronext, Immune system, PD-1, Clinical trial, Ulcerative colitis, Tissue, ISIN, Immunotherapy, Inflammation, Transplant, Mab, COVID-19, Degenerative disease, Partnership, Mnemos EP, Pancreatic cancer, Boehringer Ingelheim, Autoimmune disease, OSE, GLOBE, Fortification, Cancer, Nivolumab, IL-7, Epitope, Vaccine, Pharmaceutical industry, Euronext Paris

NANTES, France, Feb. 01, 2022 (GLOBE NEWSWIRE) -- OSE Immunotherapeutics SA (ISIN: FR0012127173; Mnemo: OSE) today announced that its shares have been transferred from compartment C to compartment B of Euronext Paris.

Key Points: 
  • NANTES, France, Feb. 01, 2022 (GLOBE NEWSWIRE) -- OSE Immunotherapeutics SA (ISIN: FR0012127173; Mnemo: OSE) today announced that its shares have been transferred from compartment C to compartment B of Euronext Paris.
  • Taking effect from January 31, 2022, this transfer is an important step recognizing significant growth of the Companys share value.
  • Compartment B includes listed companies with a market capitalization between 150 million and 1 billion euros.
  • Dominique Costantini, Chief Executive Officer of OSE Immunotherapeutics, comments: We are very pleased to announce the transfer of our shares to compartment B of Euronext Paris.

OSE Immunotherapeutics Announces Acceptance of the US Investigational New Drug (IND) Application Obtained by Veloxis Pharmaceuticals, Inc., its Partner in Transplantation, for CD28 Antagonist VEL-101/FR104

Retrieved on: 
Monday, January 31, 2022
Large-cell lung carcinoma, IND, Asahi Kasei, Ammonia, Patient, Health care, Immune system, CD28, PD-1, Immunosuppression, Food, Clinical trial, Ulcerative colitis, Dialysis, Tissue, ISIN, Immunotherapy, Inflammation, Transplant, Mab, COVID-19, Degenerative disease, Partnership, Pancreatic cancer, Boehringer Ingelheim, Autoimmune disease, OSE, GLOBE, Acquisition, Immunity, Life, Fortification, Achievement, Cancer, FDA, Nivolumab, IL-7, Solution, Epitope, Generic drug, Pharmaceutical industry, Vaccine, Dentistry

NANTES, France, Jan. 31, 2022 (GLOBE NEWSWIRE) -- OSE Immunotherapeutics (ISIN: FR0012127173; Mnemo: OSE), today announced acceptance of the IND obtained by Veloxis Pharmaceuticals, Inc. from the Food & Drug Administration (FDA) for a clinical trial with VEL-101/FR104, a CD28 antagonist monoclonal antibody fragment.

Key Points: 
  • NANTES, France, Jan. 31, 2022 (GLOBE NEWSWIRE) -- OSE Immunotherapeutics (ISIN: FR0012127173; Mnemo: OSE), today announced acceptance of the IND obtained by Veloxis Pharmaceuticals, Inc. from the Food & Drug Administration (FDA) for a clinical trial with VEL-101/FR104, a CD28 antagonist monoclonal antibody fragment.
  • Under this agreement, acceptance of the US IND application has triggered a milestone payment of 5 million from Veloxis Pharmaceuticals, Inc. to OSE Immunotherapeutics.
  • In parallel, OSE Immunotherapeutics retains all product rights to develop FR104 in autoimmune diseases.
  • Veloxis Pharmaceuticals, Inc., an Asahi Kasei company, is a fully integrated specialty pharmaceutical company committed to improving the lives of transplant patients.

OSE Immunotherapeutics Receives First Notice of Allowance of a Patent for Use of Tedopi® after Failure with PD-1 or PD-L1 Immune Checkpoint Inhibitor Treatment in HLA-A2 Positive Cancer Patients

Retrieved on: 
Tuesday, January 25, 2022
Tissue, OSE, Inflammation, American Cancer Society, Mab, CT, ICIS, Patient, Immunotherapy, GLOBE, Cancer, Autoimmune disease, ICI, NSCLC, Lung cancer, SOC, Mnemos EP, Epitope, Patent, ISIN, Fortification, Immune system, IL-7, Pancreatic cancer, Failure, Macrophage, HIV disease progression rates, Boehringer Ingelheim, Vaccination, Research, Standard of care, Severe acute respiratory syndrome coronavirus 2, B cell, Nivolumab, Docetaxel, Pemetrexed, Â, Veloxis Pharmaceuticals, PD-L1, PD-1, Partnership, COVID-19, Peptide, Prevalence, Incidence, Treatment of lung cancer, Survival rate, Degenerative disease, Population, Ulcerative colitis, Large-cell lung carcinoma, Pharmaceutical industry, Vaccine, Palladium, Uranium

NANTES, France, Jan. 25, 2022 (GLOBE NEWSWIRE) -- OSE Immunotherapeutics SA (ISIN: FR0012127173; Mnemo: OSE) today announced that the Japanese Patent Office has issued the notice of allowance for a new patent covering Tedopi®, a combination of neoepitopes, for use after failure with PD-1 or PD-L1 immune checkpoint inhibitor treatment in HLA-A2 positive cancer patients. This patent, which will further strengthen Tedopi®’s global intellectual property portfolio in immuno-oncology, will provide the product with a new protection until 2037.

Key Points: 
  • This new patent recognises the innovation of a multiepitope composition (all peptides included in Tedopi) administered after immune checkpoint inhibitor(progression of the cancer), in particular in secondary resistance situation.
  • Based on the finalized positive results of Atalante 1, we are preparing discussions with regulatory agencies on optimal paths for potential approval of Tedopi in patients with NSCLC in secondary resistance after immune checkpoint inhibitor treatment.
  • The Tedopi treatment was compared to docetaxel or pemetrexed chemotherapy (CT) treatments in this patient population, with overall survival as the primary endpoint of the trial.
  • Treatment regimens including immune checkpoint inhibitors (ICIs) have become the new standard of care for the majority of patients with NSCLC.

Preclinical Data on NT-I7 Published in Clinical Cancer Research

Retrieved on: 
Monday, January 24, 2022
Oncology, Health, Clinical Trials, Research, Science, Pharmaceutical, Biotechnology, Survival, Patient, Clinical professor, Interleukin, Mayo Clinic, Chemoradiotherapy, GBM, TMZ, Clinical Cancer Research, Novartis, NIT, Amgen, Eli Lilly, KOSDAQ, CD8, Glioblastoma, Radiation, Temozolomide, BMS, Infection, GSK, Industry, Lymphocytopenia, Company, Tumor microenvironment, Immunity, Cancer, CD4, Neoplasm, PricewaterhouseCoopers, Blood, Lymph, Principal, IL-7, Vaccine, Pharmaceutical industry, Pfizer, NT-I7, NeoImmuneTech, NT-I7, NEOIMMUNETECH

The data come from a publication titled Long-acting recombinant human interleukin-7, NT-I7, increases cytotoxic CD8 T cells and enhances survival in mouse glioma models, in the Clinical Cancer Research journal.

Key Points: 
  • The data come from a publication titled Long-acting recombinant human interleukin-7, NT-I7, increases cytotoxic CD8 T cells and enhances survival in mouse glioma models, in the Clinical Cancer Research journal.
  • These data show that NT-I7, in combination with radiation therapy, significantly prolonged survival in two glioma models dependent on the NT-I7-driven increase of CD8 T cells.
  • Some of the data contained in these documents were obtained from various external sources, and the Company has not independently verified such data.
  • Accordingly, the Company makes no representations as to the accuracy or completeness of the data, and such data involves risks and uncertainties, and is subject to change based on various factors.

OSE Immunotherapeutics Announces the Appointment of Dominique Costantini as Interim CEO Following the Departure of Alexis Peyroles

Retrieved on: 
Monday, January 17, 2022
Board, Vaccination, Research, Patient, Cancer, Inflammation, Macrophage, COVID-19, AMAL, COO, Veloxis Pharmaceuticals, Severe acute respiratory syndrome coronavirus 2, Partnership, ISIN, Growth, IL-7, CEO, Autoimmune disease, GLOBE, Pancreatic cancer, Leadership, Boehringer Ingelheim, Mnemos EP, Ulcerative colitis, Tissue, Nivolumab, OSE, Epitope, Therapy, Mab, Company, B cell, Fortification, Director, Immune system, Immunotherapy, PD-1, Degenerative disease, Large-cell lung carcinoma, Management, Vaccine, Pharmaceutical industry

NANTES, France, Jan. 17, 2022 (GLOBE NEWSWIRE) -- OSE Immunotherapeutics SA (ISIN: FR0012127173; Mnemo: OSE) today announced the departure of Alexis Peyroles as Chief Executive Officer.

Key Points: 
  • NANTES, France, Jan. 17, 2022 (GLOBE NEWSWIRE) -- OSE Immunotherapeutics SA (ISIN: FR0012127173; Mnemo: OSE) today announced the departure of Alexis Peyroles as Chief Executive Officer.
  • Dominique Costantini, current Chairwoman of OSE Immunotherapeutics Board of Directors, and previously CEO from 2012 to 2018, has been appointed interim Chief Executive Officer, effective immediately.
  • Alexis Peyroles is stepping down for health reasons and he remains committed to OSEs success.
  • Dominique Costantini, Chairwoman and Chief Executive Officer of OSE Immunotherapeutics, said: We thank Alexis for his strong involvement and wish him the very best.

NeoImmuneTech to Present at 2022 Biotech Showcase at J.P. Morgan Healthcare Conference

Retrieved on: 
Wednesday, January 5, 2022
Professional Services, Oncology, Health, Finance, Pharmaceutical, Biotechnology, PricewaterhouseCoopers, NIT, Novartis, Immunity, Company, Cancer, IL-7, Infection, Conference, BMS, GSK, MBA, KOSDAQ, Amgen, Eli Lilly, Industry, Pharmaceutical industry, Pfizer, NT-I7, NeoImmuneTech, NT-I7, NEOIMMUNETECH

NeoImmuneTech, Inc. (KOSDAQ: 950220), a clinical-stage T cell-focused biopharmaceutical company, today announced that its Chief Business Officer, Sam Zhang, Ph.D., MBA, will present at the upcoming Biotech Showcase at J.P. Morgan Healthcare Conference, to be held in a virtual format from January 10-12 and 17-19.

Key Points: 
  • NeoImmuneTech, Inc. (KOSDAQ: 950220), a clinical-stage T cell-focused biopharmaceutical company, today announced that its Chief Business Officer, Sam Zhang, Ph.D., MBA, will present at the upcoming Biotech Showcase at J.P. Morgan Healthcare Conference, to be held in a virtual format from January 10-12 and 17-19.
  • In clinical trials to date, NT-I7 has exhibited favorable PK/PD and safety profiles, both as a monotherapy and in combination with other anticancer treatments.
  • NeoImmuneTech, Inc. (NIT) is a clinical-stage T cell-focused biopharmaceutical company, dedicated to expanding the horizon of immuno-oncology and enhancing immunity to infectious diseases.
  • The statements contained herein may contain certain forward-looking statements relating to NeoImmuneTech, Inc. (the Company) that are based on its beliefs and expectations about the future.

OSE Immunotherapeutics Strengthens Leadership Team with the Appointment of Laurence de Schoulepnikoff as Chief Business Officer

Retrieved on: 
Tuesday, December 21, 2021
Linda, PD-1, CBO, Cancer, COO, IL-7, Inflammation, OSE, Tissue, Fortification, COVID-19, Leadership, Mab, Mnemos EP, Zoetis, Acceleration, GLOBE, Vaccine, B cell, Management, HEC Paris, Drug development, Epitope, Patient, Boehringer Ingelheim, ISIN, Bono, Large-cell lung carcinoma, Head, Company, Severe acute respiratory syndrome coronavirus 2, IQVIA, Immunotherapy, Science, Business development, Macrophage, Nivolumab, BMS, MBA, Business, Therapy, Drug, Alliance, Novartis, Pancreatic cancer, Vaccination, Physician, Degenerative disease, Growth, Autoimmune disease, Ulcerative colitis, Immune system, Veloxis Pharmaceuticals, Research, International, AMAL, Partnership, Fine chemical, Medicine, Pharmaceutical industry, Pharma

NANTES, France, Dec. 21, 2021 (GLOBE NEWSWIRE) -- OSE Immunotherapeutics SA (ISIN: FR0012127173; Mnemo: OSE) announces the appointment of Laurence de Schoulepnikoff as Chief Business Officer (CBO), as well as three senior appointments to further strengthen the OSE Immunotherapeutics drug development team.

Key Points: 
  • NANTES, France, Dec. 21, 2021 (GLOBE NEWSWIRE) -- OSE Immunotherapeutics SA (ISIN: FR0012127173; Mnemo: OSE) announces the appointment of Laurence de Schoulepnikoff as Chief Business Officer (CBO), as well as three senior appointments to further strengthen the OSE Immunotherapeutics drug development team.
  • Prior to AMAL, Laurence worked in mid-sized companies (Ferring International, Stragen Pharma SA) as well as in large corporate organizations (Business Development at Novartis).
  • Alexis Peyroles, Chief Executive Officer of OSE Immunotherapeutics, said: I am delighted to welcome Laurence to support our companys acceleration and lead our Business Development and Alliance Management teams.
  • OSE Immunotherapeutics is also delighted to announce the appointment of three senior executives, joining the Company to reinforce its drug development engine and help advancing its rich portfolio.

OSE Immunotherapeutics is Pleased to Announce the Continuation of its Phase 2 Trial Testing Anti-IL-7 Receptor Antagonist OSE-127/S95011 in Ulcerative Colitis after the Interim Futility Analysis

Retrieved on: 
Monday, December 13, 2021
Autoimmune disease, Interleukin 7, Vaccination, Cancer, Ulcerative colitis, Severe acute respiratory syndrome coronavirus 2, Population, Degenerative disease, COVID-19, CD127, Mab, Inflammation, IDMC, Lymphocytopenia, IL-7, OSE, Immunotherapy, PD-1, Veloxis Pharmaceuticals, Research, Fortification, Safety, Patient, Tissue, Immune system, Boehringer Ingelheim, Mnemos EP, Nivolumab, Macrophage, Epitope, GLOBE, Cytokine release syndrome, ISIN, Pancreatic cancer, B cell, Partnership, Large-cell lung carcinoma, Pharmaceutical industry, Vaccine

The primary endpoint for futility analysis was the efficacy assessment of OSE-127/S95011 versus placebo on the reduction of the modified Mayo Score*.

Key Points: 
  • The primary endpoint for futility analysis was the efficacy assessment of OSE-127/S95011 versus placebo on the reduction of the modified Mayo Score*.
  • Based on the recommendation of the trials IDMC, OSE Immunotherapeutics will proceed with the study.
  • Alexis Peyroles, Chief Executive Officer of OSE Immunotherapeutics, comments: We are pleased with the IDMC's recommendation to continue the Phase 2 trial.
  • Two independent Phase 2 studies are currently underway: in ulcerative colitis (sponsor OSE Immunotherapeutics) and in the Sjgrens syndrome (sponsor Servier).

OSE Immunotherapeutics Presents First Preclinical Efficacy Data on Anti-IL-7 Receptor Antagonist OSE-127 in Acute Lymphoblastic Leukemia

Retrieved on: 
Monday, December 13, 2021
Biomarker, Interleukin 7, Severe acute respiratory syndrome coronavirus 2, T-cell acute lymphoblastic leukemia, University of Kiel, Prognosis, BCP, Degenerative disease, OSE, PD-1, Veloxis Pharmaceuticals, Fortification, Cancer, Nivolumab, ISIN, Vaccination, B cell, CD127, T-ALL, Mab, Inflammation, Immunotherapy, Schleswig-Holstein, Safety, Boehringer Ingelheim, GLOBE, ASH, Cytokine release syndrome, Partnership, Society, Autoimmune disease, COVID-19, CD19, Research, Tissue, Mnemos EP, Macrophage, Pancreatic cancer, Large-cell lung carcinoma, Poster, University Medical Center Schleswig Holstein, Lymphocytopenia, IL-7, Patient, Ulcerative colitis, Department, University Medical Center, Immune system, Acute lymphoblastic leukemia, Epitope, University, Pharmaceutical industry, Vaccine, Diagnosis, PDX

OSE-127 is a monoclonal immunomodulatory antibody targeting the CD127 receptor, the alpha chain of the interleukin-7 receptor (IL-7R) that induces a powerful antagonist effect on effector T lymphocytes.

Key Points: 
  • OSE-127 is a monoclonal immunomodulatory antibody targeting the CD127 receptor, the alpha chain of the interleukin-7 receptor (IL-7R) that induces a powerful antagonist effect on effector T lymphocytes.
  • Despite the favourable prognosis of BCP-ALL, relapse remains a clinical challenge and novel targeted immunotherapy options are urgently needed.
  • OSE Immunotherapeutics is an integrated biotechnology company focused on developing and partnering therapies to control the immune system for immuno-oncology and autoimmune diseases.
  • OSE-230 (ChemR23 agonist mAb): first-in-class therapeutic agent with the potential to resolve chronic inflammation by driving affected tissues to tissue integrity.

OSE Immunotherapeutics Provides an Update on the First Positive Results and Clinical Development of CoVepiT, its Multi-Target T-cell Anti-COVID Vaccine

Retrieved on: 
Tuesday, November 30, 2021
NSCLC, Pancreatic cancer, Fortification, Cancer, Variants of SARS-CoV-2, Vaccination, Fever, GLOBE, B cell, MMF, Convalescence, Immunotherapy, Immune system, Organic acid, CEO, Boehringer Ingelheim, Research, OSE, ISIN, SARS, Macrophage, PD-1, Membrane protein, Degenerative disease, ELISpot, Inflammation, Nivolumab, Autoimmune disease, Large-cell lung carcinoma, Partnership, Antimetabolite, Vaccine, Omicron, Survival, Rituximab, N, Epitope, Patient, Tissue, Safety, MERS, Immunodeficiency, Severe acute respiratory syndrome coronavirus 2, Mab, COVID-19, Veloxis Pharmaceuticals, IL-7, Ulcerative colitis, Antibody, CD8, Animal, Pharmaceutical industry

Promising preclinical efficacy signals guide development in immunocompromised patients with poor antibody response to present registered anti-COVID vaccines.

Key Points: 
  • Promising preclinical efficacy signals guide development in immunocompromised patients with poor antibody response to present registered anti-COVID vaccines.
  • Results on the 6-month long-term memory T response, expected in the first quarter of 2022, will be a key element in further clinical development.
  • OSE Immunotherapeutics is an integrated biotechnology company focused on developing and partnering therapies to control the immune system for immuno-oncology and autoimmune diseases.
  • OSE-230 (ChemR23 agonist mAb): first-in-class therapeutic agent with the potential to resolve chronic inflammation by driving affected tissues to tissue integrity.